Humira's primary patents have expired in the United States, leading to the introduction of biosimilars. The original U.S. patent for adalimumab (Humira) expired in late 2016, but other patents extended its market exclusivity [1]. However, the landscape has shifted significantly, with multiple biosimilars now available [2][3].
When did Humira lose its U.S. patent exclusivity?
While the initial patent expired in 2016, AbbVie, the manufacturer of Humira, utilized a strategy of obtaining numerous secondary patents to extend market exclusivity. These later patents, related to various aspects of the drug like its formulation and method of use, were the subject of extensive litigation. Ultimately, these secondary patents have also expired or have been invalidated or settled in ways that allow biosimilar competition [4]. The first biosimilars were launched in the U.S. in July 2023 [2][3].
What is a biosimilar and how does it relate to Humira?
A biosimilar is a biological product that is highly similar to a U.S.-licensed reference biological product, such as Humira, and has no clinically meaningful differences in terms of safety, purity, and potency. Biosimilars are approved by the U.S. Food and Drug Administration (FDA) following rigorous review [5]. The availability of biosimilars for Humira is expected to increase patient access and potentially lower treatment costs [3].
Which companies have launched Humira biosimilars?
Several companies have launched Humira biosimilars in the U.S., including Amgen (Amjevita), Boehringer Ingelheim (Cyltezo), Samsung Bioepis (Hadlima), and Sandoz (Hyrimoz), among others [2][3][6]. This indicates a competitive market for adalimumab.
How does Humira's patent expiration affect drug pricing?
The expiration of patents and the subsequent entry of biosimilars typically lead to price reductions for the originator drug and the biosimilar versions. This increased competition is intended to make treatments more affordable for patients and healthcare systems [3].
What are the implications of Humira biosimilars for patients and healthcare providers?
For patients, the availability of biosimilars offers more treatment options and the potential for lower out-of-pocket costs. Healthcare providers can prescribe biosimilars interchangeably with Humira, provided the FDA has designated them as such, potentially leading to significant cost savings for their practices and patients [3][5].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/blog/humira-biosimilar-launch-date
[3] https://www.drugpatentwatch.com/blog/humira-biosimilar-competition
[4] https://www.drugpatentwatch.com/adalimumab/patents
[5] https://www.fda.gov/vaccines-blood-biologics/biosimilars/what-biosimilar-and-interchangeable-biosimilar
[6] https://www.drugpatentwatch.com/adalimumab/biosimilars